Publications by authors named "Hiromitsu Yagi"
Article Synopsis
- The study aimed to assess the safety and effectiveness of vibegron, a drug for treating overactive bladder (OAB), in Japanese patients through a real-world clinical trial over four years.
- Out of 1848 patients, 154 adverse drug reactions (ADRs) were reported, with common side effects including increased urine volume, constipation, and urinary retention, particularly affecting older male patients.
- The drug demonstrated an effectiveness rate of 88.8%, with significant improvements in OAB symptoms observed across all patient groups, making vibegron a valuable option for OAB treatment.
Objectives: To assess the effect of imidafenacin on cognitive function, including the conversion rate of mild cognitive impairment (MCI) to dementia, in a period of one year.
Methods: Patients newly administered imidafenacin to treat overactive bladder (OAB), including those who had MCI or dementia, were surveyed across Japan (cognitive safety analysis set [CSAS]), on all of whom we performed the Mini-Mental State Examination (MMSE) at baseline, 24- and 48-weeks after treatment. From CSAS, we extracted well described cases of OAB change as well as drug-related adverse events of dry mouth etc.